U.S. Software Stock News

NYSE:SN
NYSE:SNConsumer Durables

SharkNinja Adds New Accounting Leader As Shares Trade Below Targets

SharkNinja (NYSE:SN) has appointed Kaitlin Folan as Principal Accounting Officer and Chief Accounting Officer. Folan brings prior executive experience and extensive accounting expertise to the company’s finance leadership team. The change adds a new senior figure to SharkNinja’s financial oversight structure, which may interest current and prospective shareholders. For investors watching SharkNinja at a share price of $123.44, this leadership move sits alongside a mixed recent return...
NYSE:BH.A
NYSE:BH.AHospitality

Biglari Holdings Adds $500m Shelf To Fuel Growth And Flexibility

Biglari Holdings filed for a $500 million follow on equity offering and shelf registration. The filing covers the potential issuance of Class A and Class B Common Stock. The move gives the company flexibility to raise capital over time as conditions allow. For a company the size of Biglari Holdings, ticker NYSE:BH.A, a $500 million follow on shelf is a meaningful step, particularly with the stock at a current share price of $2,434.13. The filing directly relates to how the company might...
NasdaqCM:SIFY
NasdaqCM:SIFYTelecom

How Investors Are Reacting To Sify Technologies (SIFY) Data Center IPO Plans And Widening Losses

Sify Technologies reported third-quarter 2025 results with sales rising to INR 11,596 million from INR 10,491 million a year earlier, while net loss widened to INR 329 million. Management underscored strong data center momentum, plans for an IPO of its Sify Infinit Spaces subsidiary, and ongoing expansion highlighted by a new Karnataka facility, signalling a business model heavily geared toward capital-intensive infrastructure for AI-era demand. We’ll now examine how the planned IPO of Sify...
NasdaqGM:RAPT
NasdaqGM:RAPTBiotechs

GSK Buyout Turns Volatile RAPT Into Food Allergy Cash-Out Story

GSK has signed a definitive agreement to acquire RAPT Therapeutics (NasdaqGM:RAPT). The deal centers on ozureprubart, a long acting anti-IgE antibody in Phase IIb trials for food allergy prophylaxis. The transaction brings a food allergy candidate into GSK’s immunology and inflammation portfolio. RAPT Therapeutics, trading at $57.63, has recently seen very large 1 year returns and strong short term moves, with the share price up 64.2% over the past week and 60.8% over the past month. Year...
NasdaqCM:USAU
NasdaqCM:USAUMetals and Mining

Is It Too Late To Reassess U.S. Gold (USAU) After Its 207% One-Year Surge?

If you are wondering whether U.S. Gold's recent share price levels still make sense, you are not alone. This article will walk through what that price could imply about value. U.S. Gold last closed at US$22.60, with returns of 15.5% over 7 days, 0.6% over 30 days, 22.3% year to date and 207.1% over 1 year, as well as 361.2% over 3 years and 105.6% over 5 years. Those moves sit against a backdrop of ongoing interest in U.S. Gold as a materials stock, with investors reacting to sector...